Panitumumab outcome by tumour location analysis
Phase 2 PEAK study: PFS
•
Boeckx N, et al. Ann Oncol 2016;27(Suppl 6):abstract 89P (and poster).
•
†
Updated values will be included in the full publication.
68
64
60
56
52
48
44
40
36
32
28
24
20
16
12
8
4
0
0
20
40
60
80
100
Kaplan–Meier estimate
0
1
3
0
0
4
2
1
6
3
1
6
4
1
7
4
1
7
4
2
7
5
3
10
6
3
0
13
8
3
1
21
11
3
4
30
23
4
7
38
35
12
9
47
47
19
9
53
54
22
14
1:
2:
3:
4:
No. of subjects
Months
1: Pmab + FOLFOX left side
3: Pmab + FOLFOX right side
2: Bev + FOLFOX left side
4: Bev + FOLFOX right side
Median PFS, months
Pmab + FOLFOX
Bev + FOLFOX
HR (95% CI)
†
Left
14.6
11.5
NA
Right
8.7
12.6
NA
WT
RAS
